Literature DB >> 8495586

Fecal leukocytes in stool specimens submitted for Clostridium difficile toxin assay.

C E Marx1, A Morris, M L Wilson, L B Reller.   

Abstract

To determine their diagnostic utility, fecal leukocytes were sought by methylene blue stain in 502 consecutive stool specimens submitted for Clostridium difficile toxin assay. In addition, the stability of fecal leukocytes was assessed by daily examination of 23 stool specimens stored at 4 degrees C and room temperature. The sensitivity, specificity, and positive and negative predictive values of fecal leukocytes in predicting C. difficile toxin assay results were 28%, 92%, 27%, and 93%, respectively. At 4 degrees C, fecal leukocytes retained morphology for a minimum of 3 days. Leukocytes survived as long in stool specimens containing either C. difficile toxin or an enteric pathogen as they did in stool specimens with neither finding. We conclude that testing stool specimens for fecal leukocytes is not useful for predicting the presence of C. difficile toxin, because 72% of stool specimens positive for C. difficile toxin are negative for fecal leukocytes despite their stability.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8495586     DOI: 10.1016/0732-8893(93)90081-h

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  9 in total

1.  Role of stool screening tests in diagnosis of inflammatory bacterial enteritis and in selection of specimens likely to yield invasive enteric pathogens.

Authors:  R P Silletti; G Lee; E Ailey
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

Review 2.  Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors:  Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

3.  Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis.

Authors:  T S Steiner; C A Flores; T T Pizarro; R L Guerrant
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

Review 4.  Clostridium difficile infection: management strategies for a difficult disease.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Therap Adv Gastroenterol       Date:  2014-03       Impact factor: 4.409

5.  Contemporary testing for enteric pathogens: the potential for cost, time, and health care savings.

Authors:  A J Morris; P R Murray; L B Reller
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

6.  Application of rejection criteria for stool cultures for bacterial enteric pathogens.

Authors:  K Fan; A J Morris; L B Reller
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

7.  Is Fecal Leukocyte Test a good predictor of Clostridium difficile associated diarrhea?

Authors:  Savio Reddymasu; Ankur Sheth; Daniel E Banks
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-04-19       Impact factor: 3.944

8.  Clostridium difficile infection.

Authors:  Stephen A Geller; Fernando P F de Campos
Journal:  Autops Case Rep       Date:  2014-06-30

Review 9.  Infectious diarrhea.

Authors:  L Goodman; J Segreti
Journal:  Dis Mon       Date:  1999-07       Impact factor: 3.800

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.